I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista di Angiologia
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
International Angiology 2007 March;26(1):8-11
Peripheral arterial revascularization causing parallel increased activity of pro- and anti-inflammatory mediators
Parmar J. H., Aslam M., Standfield N. J.
Hammersmith Hospital, London, UK
Aim. The aim of this study was to investigate the interaction between the proinflammatory mediator interleukin (IL)-6 and anti-inflammatory mediator IL-10 in ischemia reperfusion injury following peripheral arterial revascularization.
Methods. Three groups of patients were recruited (group 1: femoral angiography alone [n=14]; group 2: radiologically successful ilio/femoral angioplasty [n=10]; and group 3: peripheral surgical bypass [n=11]). Peripheral venous blood obtained for all patients at preprocedure and at 1 h and 24 h postprocedure. After centrifugation supernatant plasma was separated and analysed for proinflammatory cytokine IL-6 and anti-inflammatory cytokine IL-10 using enzyme linked immunosorbent assay (ELISA) technique.
Results. Levels of IL-6 at 1 and 24 h were significantly higher in group 3 (P<0.05 and P<0.01, respectively) and at 24 h in group 2 as compared to group 1 (P<0.05). Levels of IL-10 were significantly higher in group 3 at 24 h (P<0.05). In group 2 levels of IL-10 higher than group 1, but this did not reach statistical significance (P=0.07).
Conclusion. Raised levels of IL-6 at 1 and 24 h in patients undergoing operative peripheral bypass suggest early and persistent proinflammatory activity, similarly patients with successful angioplasty also demonstrated similar persistent proinflammatory activity of IL-6 at 24 h. Raised levels of IL-10 at 24 h represents anti-inflammatory properties of IL-10 counter acting inflammatory response.